Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: what predicts the outcome? Experience from a developing country

Bone Marrow Transplantation volume 43, pages 481–489 (2009)Cite this article

Abstract

We analyzed the results of 108 patients (78 males and 30 females) with multiple myeloma who underwent autologous stem cell transplantation (ASCT). The median age of patients was 52 years (range, 26–68 years). High-dose melphalan (200 mg/m2) was used for conditioning. In all, 66 (61%) patients had evidence of chemo-sensitive disease before transplant. After ASCT 79.6% of patients responded: complete response 36%, very good partial response 29.6%, and partial response 13.9%. Complete response rate was higher for patients with chemo-sensitive disease; 33 of 66 (50.0%) patients achieved complete response compared with 7 of 42 (14.3%) patients with progressive disease, P<0.01. Response rates to ASCT were significantly low for patients with Hb ⩽8.5 g/dl, serum albumin ⩽3.3 g/dl, β-2 microglobulin >5.5 mg/l, International Staging System stage III at diagnosis and >12 months interval from diagnosis to transplant. Grade III–IV mucositis was the major regimen-related toxicity. At a median follow-up of 70 months, the median overall survival and event free survival (EFS) were 71 and 42 months, respectively. Estimated overall survival and EFS at 60 months were 54.4±0.05% (s.e.) and 49.3±0.05% (s.e.), respectively. Survival was significantly better for patients with pre-transplant chemo-sensitive disease and for those who achieved complete response following transplant.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Kyle R, Rajkumar SV . Multiple myeloma. Blood 2008; 111: 2962–2972.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Kumar L, Vikram P, Kochupillai V . Multiple myeloma: recent advances in management. Nat Med J India 2006; 19: 80–89.

    Google Scholar 

  3. Selby PJ, Mac Elwain TJ, Nandi AC, Ferren TJ, Powles RL, Tillyer CR et al. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 1987; 66: 55–62.

    Article  CAS  PubMed  Google Scholar 

  4. Powles R, Raje N, Milan S, Millar B, Shepherd V, Mehta J et al. Outcome assessment of a population based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment. Bone Marrow Transplant 1997; 20: 435–443.

    Article  CAS  PubMed  Google Scholar 

  5. Blade J, Esteve J, Rives S, Martínez C, Rovira M, Urbano-Ispizua A et al. High-dose therapy autotransplantation intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution. Bone Marrow Transplant 2000; 26: 845–849.

    Article  CAS  PubMed  Google Scholar 

  6. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008–4010.

    CAS  PubMed  Google Scholar 

  7. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective randomized trial of autologous bone marrow and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91–97.

    Article  CAS  PubMed  Google Scholar 

  8. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. Medical Research Council Adult Leukaemia Working Party high-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. New Engl J Med 2003; 348: 1875–1883.

    Article  CAS  PubMed  Google Scholar 

  9. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M et al High-dose therapy and autologous stem cell compared with conventional treatment in myeloma patients aged 55 to 65 years: long term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005; 23: 9227–9233.

    Article  CAS  PubMed  Google Scholar 

  10. Lenhoff S, Hjorth M, Holmberg I, Turesson I, Westin J, Nielssen JL et al. Impact on survival of high dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population based study. Blood 2000; 95: 7–11.

    CAS  PubMed  Google Scholar 

  11. Koreth J, Cutler CS, Djulbegovic B, Behl R, Schlossman RL, Munshi NC et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007; 13: 183–196.

    Article  CAS  PubMed  Google Scholar 

  12. Levy V, Katsahian S, Fermand JP, Mary JY, Chevret S . A meta-analysis on data from 575 patients with multiple myeloma randomly assigned to either high dose therapy or conventional therapy. Medicine 2005; 84: 250–260.

    Article  CAS  PubMed  Google Scholar 

  13. Kumar L, Raju GMK, Ganessan K, Shawgi S, Menon H, Wadhwa J et al. High dose chemotherapy followed by autologous stem cell transplantation in multiple myeloma. Nat Med J India 2003; 16: 16–20.

    Google Scholar 

  14. Durie BGM, Salmon SE . A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842–854.

    Article  CAS  PubMed  Google Scholar 

  15. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420.

    Article  PubMed  Google Scholar 

  16. Raju GMK, Kochupillai V, Kumar L . Storage of haematopoietic stem cells for autologous bone marrow transplantation. Nat Med J India 1995; 8: 216–221.

    CAS  Google Scholar 

  17. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA et al. Regimen related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562–1568.

    Article  CAS  PubMed  Google Scholar 

  18. Blade J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115–1123.

    Article  CAS  PubMed  Google Scholar 

  19. Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH et al. Prolonged subcutaneous administration of recombinant alpha interferon in patients with previously untreated Philadelphia chromosome positive chronic phase chronic myelogenous leukemia: effect on remission duration and survival—Cancer and Leukemia Group B study 8583. Blood 1993; 82: 2975–2984.

    CAS  PubMed  Google Scholar 

  20. Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D et al. Superiority of thalidomide and dexamethasone over vincristine–doxorubicin–dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35–39.

    Article  CAS  PubMed  Google Scholar 

  21. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021–1030.

    Article  CAS  PubMed  Google Scholar 

  22. Breitkreutz I, Lokhorst HM, Raab MS, Holt B, Cremer FW, Herrmann D et al. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia 2007; 21: 1294–1299.

    Article  CAS  PubMed  Google Scholar 

  23. Blijlevens N, Schwenkglenks M, Bacon P, D’Addio A, Einsele H, Maertens J et al. European Blood and Marrow Transplantation Mucositis Advisory Group. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy—European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 2008; 26: 1519–1525.

    Article  CAS  PubMed  Google Scholar 

  24. Spencer A, Horvath N, Gibson J, Prince HM, Herrmann R, Bashford J et al. Australasian Leukemia and Lymphoma Group. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant 2005; 35: 971–977.

    Article  CAS  PubMed  Google Scholar 

  25. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematological cancers. New Engl J Med 2004; 351: 2590–2598.

    Article  CAS  PubMed  Google Scholar 

  26. Cahill RA, Spitzer TR, Mazumder A . Marrow engraftment and clinical manifestations of capillary leak syndrome. Bone Marrow Transplant 1996; 18: 177–184.

    CAS  PubMed  Google Scholar 

  27. Mossad S, Kalaycio M, Sobecks R, Pohlman B, Andresen S, Avery R et al. Steroids prevent engraftment syndrome after autologous hematopoietic stem cell transplantation without increasing the risk of infection. Bone Marrow Transplant 2005; 35: 375–381.

    Article  CAS  PubMed  Google Scholar 

  28. Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 14: 822–829.

    Article  Google Scholar 

  29. van de Velde HJ, Liu X, Chen G, Cakana A, Deraedt W, Bayssas M . Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007; 92: 1399–1406.

    Article  PubMed  Google Scholar 

  30. Pineda-Roman M, Bolejack V, Arzoumanian V, Anaissie E, van Rhee F, Zangari M et al. Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. Br J Haematol 2007; 136: 393–399.

    Article  PubMed  Google Scholar 

  31. O’Shea D, Giles C, Terpos E, Perz J, Politou M, Sana V et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single centre experience in 211 patients. Bone Marrow Transplant 2006; 37: 731–737.

    Article  PubMed  Google Scholar 

  32. Krejci M, Buchler T, Hajeck R, Svobodnik A, Krivanova A, Pour L et al. Prognostic factors for survival after autologous transplantation : a single centre experience in 133 multiple myeloma patients. Bone Marrow Transplant 2005; 35: 159–164.

    Article  CAS  PubMed  Google Scholar 

  33. Nadal E, Gine E, Blade J, Esteve J, Rosifiol L, Fernandez Aviles F et al. High dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission. Bone Marrow Transplant 2004; 33: 61–64.

    Article  CAS  PubMed  Google Scholar 

  34. Alexanian R, Weber D, Giralt S, Dimoopoules M, Delasalle K, Smith T et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27: 1037–1043.

    Article  CAS  PubMed  Google Scholar 

  35. International Bone Marrow Transplant Registry/Autologous Blood & Marrow Transplant Registry (IBMTR/ABMTR). News Letter 2000; 7: 3–10.

  36. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C et al. High dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma. Upfront or rescue treatment? Results of a multicenter sequential randomized trial. Blood 1998; 92: 3131–3136.

    CAS  PubMed  Google Scholar 

  37. Sengar M, Kumar L, Ganessan K, Mohanty S, Wadhwa J, Kochupillai V . Role of post transplant maintenance therapy in multiple myeloma: results from a developing country. Proc Am Soc Clin Oncol 2005; 24: 6731 (abstract).

    Article  Google Scholar 

  38. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L et al. Inter-Groupe Francophone du Myélome (IFM). Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108: 3289–3294.

    Article  CAS  PubMed  Google Scholar 

  39. Haessler J, Shaughnessy Jr JD, Zhan F, Crowley J, van Rhee F, Epstein J et al. Benefit of complete response in multiple myeloma limited to high risk subgroup identified by gene expression profiling. Clin Cancer Res 2007; 13: 7073–7079.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We acknowledge the excellent care and dedication of residents and nursing staff of the Medical Oncology Department. Mr Shanti Swaroop and Narendra Singh helped in harvesting of stem cells and Ms Mercy helped with cryopreservation of stem cells.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

    L Kumar, J Ghosh, P Ganessan, A Gupta, R Hariprasad & V Kochupillai

Authors
  1. L Kumar
    View author publications

    Search author on:PubMed Google Scholar

  2. J Ghosh
    View author publications

    Search author on:PubMed Google Scholar

  3. P Ganessan
    View author publications

    Search author on:PubMed Google Scholar

  4. A Gupta
    View author publications

    Search author on:PubMed Google Scholar

  5. R Hariprasad
    View author publications

    Search author on:PubMed Google Scholar

  6. V Kochupillai
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to L Kumar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kumar, L., Ghosh, J., Ganessan, P. et al. High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: what predicts the outcome? Experience from a developing country. Bone Marrow Transplant 43, 481–489 (2009). https://doi.org/10.1038/bmt.2008.343

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/bmt.2008.343

Keywords

This article is cited by

Search

Advanced search

Quick links